On Jun. 1, 2020, the FDA issued an emergency use authorization (EUA) for Impella RP to include patients suffering from COVID-19 related right heart failure or decompensation, including pulmonary embolism (PE). Abiomed manufactures Impella RP.

Impella RP is a temporary heart pump that provides circulatory support for patients who develop right side ventricular failure.. In 2017, Impella RP received FDA approval as safe and effective for treating right ventricular failure in the setting of acute myocardial infarction and after cardiac surgery.